



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## LRRK2-IN-14

Cat. No.:	HY-158365
CAS No.:	2942328-06-3
Molecular Formula:	C <sub>17</sub> H <sub>18</sub> F <sub>3</sub> N <sub>5</sub> O <sub>2</sub>
Molecular Weight:	381.35
Target:	LRRK2
Pathway:	Autophagy
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	LRRK2-IN-14 (Compound 8) is an orally active LRRK2 inhibitor. LRRK2-IN-14 has an IC <sub>50</sub> of 6.3 nM for LRRK2(G2019S) cell activity. LRRK2-IN-14 has an inhibitory effect on hERG (IC <sub>50</sub> =22 μM). LRRK2-IN-14 has blood-brain barrier permeability <sup>[1]</sup> .																																																								
<b>In Vivo</b>	<p>LRRK2-IN-14 (30 mg/kg; p.o.; single dose) inhibits phosphorylation of G2019S mutant LRRK2 in the brain in ICR mice<sup>[1]</sup>.</p> <p>Pharmacokinetic Analysis in ICR mice<sup>[1]</sup></p> <table border="1"> <thead> <tr> <th>Route</th> <th>Dose (mg/kg)</th> <th>C<sub>0</sub> (ng/mL)</th> <th>C<sub>max</sub> (ng/mL)</th> <th>T<sub>max</sub> (h)</th> <th>t<sub>1/2</sub> (h)</th> <th>V<sub>dss</sub> (mL/kg)</th> <th>Cl<sub>obs</sub> (mL/min/kg)</th> <th>AUC<sub>0-last</sub> (ng·h/mL)</th> <th>AUC<sub>0-INF</sub> (ng·h/mL)</th> <th>MRT<sub>0-INF</sub> (h)</th> <th>F (%)</th> </tr> </thead> <tbody> <tr> <td>i.v.</td> <td>5</td> <td>4101</td> <td>/</td> <td>/</td> <td>0.905</td> <td>1233</td> <td>16.3</td> <td>5122</td> <td>5181</td> <td>1.27</td> <td>/</td> </tr> <tr> <td>p.o.</td> <td>5</td> <td>/</td> <td>2803</td> <td>0.083</td> <td>0.709</td> <td>/</td> <td>/</td> <td>3657</td> <td>3672</td> <td>1.22</td> <td>70.9</td> </tr> <tr> <td>brain</td> <td>5</td> <td>/</td> <td>837</td> <td>0.292</td> <td>0.648</td> <td>/</td> <td>/</td> <td>1230</td> <td>1233</td> <td>1.14</td> <td>/</td> </tr> </tbody> </table> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>ICR mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>30 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>p.o.; single dose</td> </tr> <tr> <td>Result:</td> <td>Reduced phosphorylated LRRK2 levels to 34%.</td> </tr> </table>	Route	Dose (mg/kg)	C <sub>0</sub> (ng/mL)	C <sub>max</sub> (ng/mL)	T <sub>max</sub> (h)	t <sub>1/2</sub> (h)	V <sub>dss</sub> (mL/kg)	Cl <sub>obs</sub> (mL/min/kg)	AUC <sub>0-last</sub> (ng·h/mL)	AUC <sub>0-INF</sub> (ng·h/mL)	MRT <sub>0-INF</sub> (h)	F (%)	i.v.	5	4101	/	/	0.905	1233	16.3	5122	5181	1.27	/	p.o.	5	/	2803	0.083	0.709	/	/	3657	3672	1.22	70.9	brain	5	/	837	0.292	0.648	/	/	1230	1233	1.14	/	Animal Model:	ICR mice <sup>[1]</sup>	Dosage:	30 mg/kg	Administration:	p.o.; single dose	Result:	Reduced phosphorylated LRRK2 levels to 34%.
Route	Dose (mg/kg)	C <sub>0</sub> (ng/mL)	C <sub>max</sub> (ng/mL)	T <sub>max</sub> (h)	t <sub>1/2</sub> (h)	V <sub>dss</sub> (mL/kg)	Cl <sub>obs</sub> (mL/min/kg)	AUC <sub>0-last</sub> (ng·h/mL)	AUC <sub>0-INF</sub> (ng·h/mL)	MRT <sub>0-INF</sub> (h)	F (%)																																														
i.v.	5	4101	/	/	0.905	1233	16.3	5122	5181	1.27	/																																														
p.o.	5	/	2803	0.083	0.709	/	/	3657	3672	1.22	70.9																																														
brain	5	/	837	0.292	0.648	/	/	1230	1233	1.14	/																																														
Animal Model:	ICR mice <sup>[1]</sup>																																																								
Dosage:	30 mg/kg																																																								
Administration:	p.o.; single dose																																																								
Result:	Reduced phosphorylated LRRK2 levels to 34%.																																																								

### REFERENCES

[1]. Kim K, et al. Concurrent Optimizations of Efficacy and Blood-Brain Barrier Permeability in New Macrocyclic LRRK2 Inhibitors for Potential Parkinson's Disease

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA